

Patrice Chevallier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8685442/publications.pdf>

Version: 2024-02-01

231
papers

4,407
citations

168829

31
h-index

145109

60
g-index

234
all docs

234
docs citations

234
times ranked

4951
citing authors

#	ARTICLE	IF	CITATIONS
1	Post-SARS-CoV-2 vaccination specific antibody decrease : Let's get the half-full glass perspective. Journal of Infection, 2022, 84, 94-118.	1.7	2
2	Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. British Journal of Haematology, 2022, 196, 360-362.	1.2	24
3	Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant. British Journal of Haematology, 2022, 196, .	1.2	21
4	Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood, 2022, 139, 134-137.	0.6	59
5	Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma: Phase 2 study. Cancer Medicine, 2022, 11, 1292-1298.	1.3	10
6	Anti-SARS-CoV-2 vaccines in recipient and/or donor before allotransplant. EJHaem, 2022, , .	0.4	4
7	B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 279.e1-279.e4.	0.6	10
8	SARS-CoV-2 T-Cell Responses in Allogeneic Hematopoietic Stem Cell Recipients following Two Doses of BNT162b2 mRNA Vaccine. Vaccines, 2022, 10, 448.	2.1	24
9	Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program. Journal of Clinical Virology, 2022, 148, 105106.	1.6	10
10	Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients. Hematological Oncology, 2022, 40, 1097-1099.	0.8	8
11	Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide. Acta Oncologica, 2021, 60, 466-474.	0.8	4
12	FLT3 ligand in acute myeloid leukemia: a simple test with deep implications. Leukemia and Lymphoma, 2021, 62, 264-270.	0.6	4
13	Scoring system for clinically significant CMV infection in seropositive recipients following allogeneic hematopoietic cell transplant: an SFGM-TC study. Bone Marrow Transplantation, 2021, 56, 1305-1315.	1.3	13
14	Post-transplantation cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-identical sibling donors: A retrospective analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2021, 127, 209-218.	2.0	26
15	Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer, 2021, 127, 372-380.	2.0	25
16	Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study. American Journal of Hematology, 2021, 96, 80-88.	2.0	17
17	Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood, 2021, 137, 751-762.	0.6	183
18	Therapeutic targets in childhood B-acute lymphoblastic leukemia: what about HER2/neu?. Hematological Oncology, 2021, 39, 270-272.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem cells recipients. <i>EJHaem</i> , 2021, 2, 520-524.	0.4	28
20	A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3511-3514.	1.4	12
21	Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide. <i>Cancer Medicine</i> , 2021, 10, 7194-7202.	1.3	4
22	Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. <i>British Journal of Haematology</i> , 2021, 195, 417-428.	1.2	9
23	Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2021, 4, e2126344.	2.8	55
24	Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 839.e1-839.e6.	0.6	18
25	Early Post-Transplantation Serum Ferritin Level Predicts Survival in Recipients of Haploidentical Stem Cell Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 861.e1-861.e7.	0.6	0
26	A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 642-648.	1.3	6
27	Diagnosis and prognosis are supported by integrated assessment of next-generation sequencing in chronic myeloid malignancies. A real-life study. <i>Haematologica</i> , 2021, 106, 701-707.	1.7	10
28	<i>KMT2A-CBL</i> rearrangements in acute leukemias: clinical characteristics and genetic breakpoints. <i>Blood Advances</i> , 2021, 5, 5617-5620.	2.5	1
29	Onset of Blast Crises in CML Patients in Treatment-Free Remission: Descriptive Analysis of 4 Cases. <i>Blood</i> , 2021, 138, 2556-2556.	0.6	0
30	The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study. <i>Blood</i> , 2021, 138, 512-512.	0.6	9
31	Post-Transplantation Cyclophosphamide for Gvhd Prophylaxis in Related and Unrelated Allogeneic Hematopoietic Cell Transplantation: Study from the SFGM-TC Registry. <i>Blood</i> , 2021, 138, 2883-2883.	0.6	0
32	Profound B-Cell Lymphopenia Is a Major Factor Predicting Poor Humoral Response after BNT162b2 mRNA Sars-Cov-2 Vaccines in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3911-3911.	0.6	1
33	Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study. <i>Blood</i> , 2021, 138, 511-511.	0.6	10
34	Interest of a Third Dose of BNT162b2 Anti-Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Stem-Cells Recipients. <i>Blood</i> , 2021, 138, 3908-3908.	0.6	0
35	Peripheral Levels of Monocytic Myeloid-Derived Suppressive Cells at Diagnosis Predict Survivals in AML Patients Eligible for Intensive Chemotherapy. <i>Blood</i> , 2021, 138, 3465-3465.	0.6	0
36	Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study. <i>Blood</i> , 2021, 138, 215-215.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk". Blood, 2021, 138, 1842-1842.	0.6	2
38	Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients. Blood, 2021, 138, 1844-1844.	0.6	0
39	Antibody Response after One and/or Two Doses of BNT162b2 Anti-Sars-Cov-2 mRNA Vaccine in Patients Treated By CAR T-Cells Therapy. Blood, 2021, 138, 254-254.	0.6	1
40	Comparable Outcomes Among Adult Patients Allografted for Myelodysplastic Syndrome Using Haploidentical, Matched Unrelated or Matched Sibling Donors: A Single-Center Study. Blood, 2021, 138, 4914-4914.	0.6	0
41	Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia: Why Do Adolescents and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Blood, 2021, 138, 2921-2921.	0.6	0
42	CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM. Blood, 2021, 138, 243-243.	0.6	18
43	Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program. Blood, 2021, 138, 262-262.	0.6	7
44	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. Blood, 2021, 138, 2920-2920.	0.6	1
45	A Prospective Phase 2 Study Testing High Dose Post-Transplant Cyclophosphamide As Sole Gvhd Prophylaxis after Matched Allograft Using Baltimore-Based Reduced-Intensity Conditioning Regimens and PBSC As Source of Graft. Blood, 2021, 138, 1812-1812.	0.6	1
46	Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients. Blood, 2021, 138, 336-336.	0.6	2
47	Sars-Cov-2 T-Cell Response in Allogeneic Hematopoietic Stem Cell Recipients Following Two Doses of BNT162b2 Vaccine. Blood, 2021, 138, 2895-2895.	0.6	0
48	Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2021, 138, 3964-3964.	0.6	0
49	Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft-versus-host disease. World Journal of Gastroenterology, 2021, 27, 7792-7800.	1.4	5
50	Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft. Scientific Reports, 2020, 10, 15399.	1.6	3
51	Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide. Annals of Hematology, 2020, 99, 1341-1350.	0.8	7
52	Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire (SFGM-TC). Journal of Hematology and Oncology, 2020, 13, 56.	6.9	31
53	Sequential allogeneic hematopoietic stem cell transplantation for active refractory/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Annals of Hematology, 2020, 99, 1855-1862.	0.8	13
54	Clinical and economic impact of treated CMV infection in adult CMV�seropositive patients after allogeneic hematopoietic cell transplantation. Journal of Medical Virology, 2020, 92, 3665-3673.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Therapeutic Targets in Childhood B-Acute Lymphoblastic Leukemia : What about HER2/Neu?. Blood, 2020, 136, 15-16.	0.6	0
56	Values of Hematopoietic Cell Transplantation-Specific Comorbidity Index, Comorbidity/Age Index and Augmented Comorbidity/Age Index in Recipients of Haploidentical Stem Cell Transplantation Using Ptcy As Gvhd Prophylaxis: A Retrospective Study of 223 Cases. Blood, 2020, 136, 37-38.	0.6	0
57	Hematopoietic stem cell transplantation for adult patients with isolated <i>NPM1</i> mutated acute myeloid leukemia in first remission. American Journal of Hematology, 2019, 94, 231-239.	2.0	15
58	Allogeneic Stem Cell Transplantation in Therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2366-2374.	2.0	3
59	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood, 2019, 134, 1351-1355.	0.6	89
60	Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplantation, 2019, 54, 1815-1826.	1.3	75
61	FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia. Cytokine, 2019, 120, 85-87.	1.4	1
62	Eltrombopag induces major non-�toxic hypersiderraemia. British Journal of Haematology, 2019, 186, 365-366.	1.2	2
63	Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies. Biology of Blood and Marrow Transplantation, 2019, 25, 1465-1471.	2.0	2
64	Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Bone Marrow Transplantation, 2019, 54, 1586-1594.	1.3	30
65	Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT. Blood Cancer Journal, 2019, 9, 88.	2.8	39
66	The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party. Biology of Blood and Marrow Transplantation, 2019, 25, 86-93.	2.0	21
67	Targeting cell-bound MUC1 on myelomonocytic, monocytic leukemias and phenotypically defined leukemic stem cells with anti-SEA module antibodies. Experimental Hematology, 2019, 70, 97-108.	0.2	3
68	Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients. Biology of Blood and Marrow Transplantation, 2019, 25, 906-911.	2.0	6
69	FLT3 ligand plasma levels in acute myeloid leukemia. Haematologica, 2019, 104, e240-e243.	1.7	8
70	Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2019, 134, 4555-4555.	0.6	3
71	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. Blood, 2019, 134, 1295-1295.	0.6	4
72	The Combination of Venetoclax and Tofacitinib Induced Hematological Responses in Patients with Relapse/ Refractory T-ALL with BCL2 Expression and Surface IL7R Expression or IL7R-Pathway Mutations (On behalf of the GRAALL). Blood, 2019, 134, 1339-1339.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 3319-3319.	0.6	0
74	Profound Lymphopenia at the Time of ATG Administration Is Not Predictive of Survivals after Allogeneic Transplant Using Purine Analogue/Busulfan-Based Conditioning Regimen. <i>Blood</i> , 2019, 134, 1985-1985.	0.6	0
75	Multicentric Real Life Evaluation of the Impact of Next-Generation Sequencing on the Clinical Management of Chronic Myeloid Malignancies. <i>Blood</i> , 2019, 134, 5771-5771.	0.6	0
76	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. <i>Cancer</i> , 2018, 124, 2134-2141.	2.0	30
77	Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , 2018, 53, 1044-1047.	1.3	6
78	Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 751-757.	2.0	39
79	Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 431-437.	1.3	37
80	Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Soci�t� Francophone de Greffe de Moelle et de Th�rapie Cellulaire. <i>American Journal of Hematology</i> , 2018, 93, 416-423.	2.0	18
81	Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. <i>Haematologica</i> , 2018, 103, 2033-2039.	1.7	24
82	The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2018, 132, 3460-3460.	0.6	1
83	Blinatumomab + Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience. <i>Blood</i> , 2018, 132, 4014-4014.	0.6	14
84	The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial. <i>Blood</i> , 2018, 132, 1444-1444.	0.6	9
85	Results of Autologous and Allogeneic Transplantation in Patients with Primary Plasma Cell Leukemia: A Large Retrospective Analysis of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2018, 132, 3425-3425.	0.6	3
86	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. <i>Blood</i> , 2018, 132, 708-708.	0.6	4
87	Nilotinib (Tasigna�) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). <i>Blood</i> , 2018, 132, 31-31.	0.6	36
88	Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Elderly Patients with Acute Myeloid Leukemia in First Complete Remission: A Time-Dependent and Multistate Analysis from the French Innovative Leukemia Organization. <i>Blood</i> , 2018, 132, 209-209.	0.6	4
89	Impact on early outcomes and immune reconstitution of high-dose post-transplant cyclophosphamide vs anti-thymocyte globulin after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <i>Oncotarget</i> , 2018, 9, 11451-11464.	0.8	46
90	Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies. <i>Oncotarget</i> , 2018, 9, 33528-33535.	0.8	17

#	ARTICLE	IF	CITATIONS
91	Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC. <i>Oncotarget</i> , 2018, 9, 36603-36612.	0.8	6
92	Allogeneic Stem Cell Transplantation from Unmanipulated Haploidentical Donors Versus Matched or Mismatched 9/10 Unrelated Donors in Acute Lymphoblastic Leukemia in First Complete Remission: On Behalf of the ALWP of the EBMT. <i>Blood</i> , 2018, 132, 2174-2174.	0.6	0
93	Better Outcome in Children Compared to AYAs and Young Adults after Allogeneic HSCT for AML: A Multicenter Retrospective Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM -TC). <i>Blood</i> , 2018, 132, 3449-3449.	0.6	0
94	Comorbidity-Associated Risk of Overall Mortality Following Hematopoietic Stem-Cell Transplantation Is Regimen-Dependent: A Study from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2018, 132, 203-203.	0.6	0
95	Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of the Francophone Society for Stem Cell Transplantation and Cell Therapy. <i>Blood</i> , 2018, 132, 3447-3447.	0.6	0
96	Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party. <i>Blood</i> , 2018, 132, 2143-2143.	0.6	2
97	No Influence of Peripheral Blood CD34+ and CD3+ Graft Cell Counts on Outcomes after Reduced-Intensity Conditioning Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2018, 132, 4577-4577.	0.6	0
98	Allogeneic Hematopoietic Stem-Cell Transplantation for Patients with Richter's Syndrome:the SFGM-TC Experience. <i>Blood</i> , 2018, 132, 3457-3457.	0.6	0
99	Clinical Outcome Associated with Cytomegalovirus (CMV) Infection/Disease in CMV-Seropositive Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 3382-3382.	0.6	0
100	Outcomes of Salvage Haploidentical Transplant with Post-Transplant Cyclophosphamide for Rescuing Primary Graft Failure Patients : A Report By the SFGM-TC. <i>Blood</i> , 2018, 132, 4663-4663.	0.6	0
101	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	1.7	6
102	Impact of stem cell graft on early viral infections and immune reconstitution after allogeneic transplantation in adults. <i>Journal of Clinical Virology</i> , 2017, 93, 30-36.	1.6	13
103	Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and <sc>JAK</sc> inhibitors era?. <i>European Journal of Haematology</i> , 2017, 99, 60-69.	1.1	5
104	Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 184-191.	1.7	43
105	Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Adult Patients with t(4;11)(q21;q23) <i>KMT2A/AFF1 (MLL/AF4)</i> B-Acute Lymphoblastic Leukemia in First Complete Remission (CR1): Favorable Outcome of Patients with Negative Minimal Residual Disease (MRD) Status at Transplant. a Report from the Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation (ALWP-EBMT). <i>Blood</i> , 2017, 130, 663-663.	0.6	0
106	Outcomes of Graft Failures after Umbilical Cord Blood Transplantation in Acute Leukemia: A Study from Eurocord and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2017, 130, 661-661.	0.6	0
107	Immunotherapy for B acute lymphoblastic leukemia. <i>Hematologie</i> , 2016, 22, 39-48.	0.0	0
108	Higher Early Monocyte and Total Lymphocyte Counts Are Associated with Better Overall Survival after Standard Total Body Irradiation, Cyclophosphamide, and Fludarabine Reduced-Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1473-1479.	2.0	9

#	ARTICLE	IF	CITATIONS
109	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-“positive ALL. <i>Blood</i> , 2016, 128, 774-782.	0.6	243
110	Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients. <i>Seminars in Hematology</i> , 2016, 53, 216-217.	1.8	3
111	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 1044-1053.	13.9	270
112	Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party. <i>Haematologica</i> , 2016, 101, 884-890.	1.7	30
113	Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS. <i>Cancer Medicine</i> , 2016, 5, 3068-3076.	1.3	13
114	Radioimmunotherapy for Treatment of Acute Leukemia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 135-146.	2.5	31
115	Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1162-1162.	0.6	11
116	Comparison of Haematopoietic Stem Cell Transplantation Approaches in Primary Plasma Cell Leukaemia. <i>Blood</i> , 2016, 128, 2293-2293.	0.6	2
117	Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study. <i>Blood</i> , 2016, 128, 2776-2776.	0.6	4
118	A Phase I/II Study of Vaccination By Autologous Leukemic Apoptotic Corpse Pulsed Dendritic Cells for Elderly Acute Myeloid Leukemia Patients in First or Second Complete Remission (LAM DC trial). <i>Blood</i> , 2016, 128, 2821-2821.	0.6	3
119	Hyper-CVAD Plus Epratuzumab As Salvage Regimen for Younger Relapsed/Refractory CD22+ B Acute Lymphoblastic Leukemia (ALL) Patients: Results of the Phase 2 Prospective Cheprall Study. <i>Blood</i> , 2016, 128, 4018-4018.	0.6	4
120	Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 4661-4661.	0.6	1
121	CD38 Expression in B-Lineage Acute Lymphoblastic Leukemia, a Possible Target for Immunotherapy. <i>Blood</i> , 2016, 128, 5268-5268.	0.6	5
122	High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia -“ an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Oncotarget</i> , 2016, 7, 27255-27266.	0.8	53
123	Relapse Risk Score after Allogeneic Stem Cell Transplantation for MDS Patients. an EBMT Study from the MDS Subcommittee of Chronic Malignancies Working Party (CMWP). <i>Blood</i> , 2016, 128, 4701-4701.	0.6	0
124	Refined Graft-Versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate and Unfavorable Prognosis Acute Myeloid Leukemia Transplanted in First Complete Remission from HLA-Identical Related or Unrelated Donors: A Retrospective Study on Behalf of the ALWP of the EBMT. <i>Blood</i> , 2016, 128, 4643-4643.	0.6	0
125	Association Between Multiple Mismatches at the HLA-DPB1 and DRB3/4/5 Genes and Adverse Outcomes in HLA-a, -B, -C, -DRB1 and -DQB1 Identical Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI). <i>Blood</i> , 2016, 128, 4660-4660.	0.6	0
126	Autologous Versus Related Versus Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with NPM1 Mutated/FLT3-ITD Negative Acute Myeloid Leukemia in First Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 2279-2279.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Engraftment of Donor Cells after Allogeneic Stem Cell Transplantation: Comparison and Impact of Chimerism in Whole Blood and Peripheral CD3+ T-Cells. <i>Blood</i> , 2016, 128, 5866-5866.	0.6	0
128	Reduced-Intensity (FB2) Vs Reduced-Toxicity Myeloablative (FB3/FB4) Fludarabine/Busulfan Based Conditioning Regimens for Non-Hodgkin Lymphoma (NHL) Allografted Adult Patients: A Retrospective Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2016, 128, 980-980.	0.6	0
129	Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3467-3467.	0.6	0
130	Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia (AML) with Complex Karyotypes (CK): A Retrospective Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) and MD Anderson Cancer Center (MDACC). <i>Blood</i> , 2016, 128, 3479-3479.	0.6	0
131	In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR). <i>Blood</i> , 2016, 128, 5193-5193.	0.6	0
132	Development of a Risk Score for Prediction of Overall Survival Following Umbilical Cord Blood Transplantation in Acute Leukemia Patients: A Study from the Acute Leukemia Working Party (WP) and Paediatric Disease WP of the European Society for Blood and Marrow Transplantation (EBMT), and Eurocord. <i>Blood</i> , 2016, 128, 1169-1169.	0.6	2
133	Triage Scoring System Based on Early Post-Transplant Complications for Patients with Myelodysplastic Syndrome Requiring ICU after Allo-HCT: An SFGM-TC Study. <i>Blood</i> , 2016, 128, 3470-3470.	0.6	0
134	A Composite Event-Free Survival End Point to Evaluate Outcome after Allogeneic Transplantation for Severe Aplastic Anemia: A Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). <i>Blood</i> , 2016, 128, 2674-2674.	0.6	0
135	Low Incidence of Chronic Gvhd after Haploidentical T-Cell Replete Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide (PT-Cy). <i>Blood</i> , 2016, 128, 4594-4594.	0.6	0
136	Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry. <i>Blood</i> , 2016, 128, 3476-3476.	0.6	0
137	Is Arsenic Trioxide (ATO) Required in the Treatment of High Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL2006) By the French Belgian Swiss APL Group. <i>Blood</i> , 2016, 128, 895-895.	0.6	0
138	Single HLA Mismatch Unrelated Donor Allogeneic Stem Cell Transplantation in Caucasian Recipients: Outcomes in HLA-A, -B, -C, -DRB1 and -DQB1 Mismatch Hematopoietic Stem Cell Transplantation: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society for Histocompatibility and Immunogenetics (SFHI). <i>Blood</i> , 2016, 128, 3474-3474.	0.6	0
139	Outcomes of Mismatched Related Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: A Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , 2016, 128, 3504-3504.	0.6	0
140	Comparable Outcomes after Allogeneic Stem-Cell Transplantation with Intravenous Busulfan or Treosulfan-Based Reduced-Intensity and Reduced Toxicity Regimens in Acute Myeloid Leukemia. a Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 2280-2280.	0.6	5
141	Evaluation of Infectious Complications after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Following Reduced-Intensity and Myeloablative Conditioning: A Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC) Study. <i>Blood</i> , 2016, 128, 5758-5758.	0.6	0
142	Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. <i>Blood</i> , 2015, 126, 1027-1032.	0.6	69
143	Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 2486-2496.	0.6	233
144	Use of killer cell immunoglobulin-like receptor genes as early markers of hematopoietic chimerism after double-umbilical cord blood transplantation. <i>Haematologica</i> , 2015, 100, e475-e479.	1.7	5

#	ARTICLE	IF	CITATIONS
145	The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. <i>Haematologica</i> , 2015, 100, 683-689.	1.7	36
146	Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. <i>Annals of Hematology</i> , 2015, 94, 663-669.	0.8	4
147	90 Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. <i>Lancet Haematology</i> , the, 2015, 2, e108-e117.	2.2	36
148	Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Societ� Fran�aise de Greffe de Moelle et Therapie Cellulaire. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1515-1523.	2.0	11
149	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015, 100, e128-e131.	1.7	26
150	Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto�SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM�TC. <i>European Journal of Haematology</i> , 2015, 94, 449-455.	1.1	10
151	Complete Donor T Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced-Intensity Conditioning Regimen Allogeneic Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 180-184.	2.0	16
152	Allogeneic Hematopoietic Cell Transplantation for Adult Patients with ALL: Current Results and Prognostic Factors. an Analysis from Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3202-3202.	0.6	1
153	Selecting Double Cord Blood Units for Adults with Hematological Malignancies: Impact of ABO, HLA and Cell Dose on Outcomes after Double Cord Blood Transplants a CBC-Cellular Therapy & Immunobiology Working Party, EBMT and Eurocord Study. <i>Blood</i> , 2015, 126, 3214-3214.	0.6	1
154	Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group. <i>Blood</i> , 2015, 126, 451-451.	0.6	3
155	Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA). <i>Blood</i> , 2015, 126, 679-679.	0.6	39
156	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 4364-4364.	0.6	0
157	Post-Transplant Cyclophosphamide (PTCY) Vs Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) in Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Immune Reconstitution. <i>Blood</i> , 2015, 126, 1955-1955.	0.6	0
158	Comparison of Matched/Mismatched Unrelated Donor Stem Cell Transplantation to Autologous Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 3216-3216.	0.6	0
159	Larger Number of Invariant Natural Killer T-Cells in Allogeneic Peripheral Blood Stem Cell Grafts Is Associated with Improved Graft-Versus-Host Disease-Free, Progression-Free Survival after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 514-514.	0.6	1
160	A Machine Learning Based Model to Predict Two-Year Leukemia Free Survival in Cord Blood Transplantation for Acute Leukemia - a Data Mining Study, on Behalf of Eurocord, Cord Blood Committee and the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , 2015, 126, 3211-3211.	0.6	3
161	Allogeneic Stem Cell Transplantation for Primary or Secondary Myelofibrosis: A Retrospective Intent-to-Treat Analysis and Impact of Mutational Status and JAK1/2 Inhibitor Ruxolitinib Prescription in Patients Who Cannot Proceed to Transplantation. <i>Blood</i> , 2015, 126, 3218-3218.	0.6	0
162	Targeting Cell-Bound MUC1 on Myelomonocytic and Monocytic Leukemias and Leukemic Stem Cells: Therapeutic Implications. <i>Blood</i> , 2015, 126, 2899-2899.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Post-Transplant Cyclophosphamide (PTCY) Versus Anti-Thymoglobulin (ATG) As Part of the Gvhd Prophylaxis for Fludarabine/Clofarabine/Busulfan Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT): Influence on Early Outcomes. <i>Blood</i> , 2015, 126, 4339-4339.	0.6	0
164	RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC) Tj ETQq00 0 rgBT /Overlock	0.6	0
165	Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC). <i>Blood</i> , 2015, 126, 4367-4367.	0.6	0
166	Second-Generation Relative Donor for T-Replete Haplo-Identical Allogeneic Stem Cell Transplantation with High-Dose Post-Transplant Cyclophosphamide: Towards Disappearance of the HLA Barrier. <i>Blood</i> , 2015, 126, 5519-5519.	0.6	0
167	CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC. <i>Blood</i> , 2015, 126, 1908-1908.	0.6	0
168	Expansion of T or B Lymphocytes after Unrelated Cord Blood (UCB) Allogeneic Stem Cell Transplantation in Adults Correlates with CMV Reactivation and Is Associated with a Better Outcome. <i>Blood</i> , 2015, 126, 1947-1947.	0.6	0
169	No Advantages of Fractionated Versus Single Dose(s) of Gemtuzumab Ozogamicin (GO) As Part of the Midam Salvage Regimen in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients. <i>Blood</i> , 2015, 126, 2520-2520.	0.6	1
170	Impact of NK Cell Reconstitution and Recipient HLA-C Typing on Clinical Outcome after Reduced Intensity Cord Blood Transplant: Results of a Prospective Phase II Multicentric Trial on Behalf of Societe Francaise De Greffe De Moelle Osseuse Et Therapie Cellulaire (SFGM-TC) and Eurocord. <i>Blood</i> , 2015, 126, 4393-4393.	0.6	0
171	Impact of Pre-Transplant Diffusion Lung Capacity for Nitric Oxide (DLNO) and of Dlno/Pre-Transplant Diffusion Lung Capacity for Carbon Monoxide (DLNO/DLCO) Ratio on Pulmonary Outcomes in Adults Receiving Allogeneic Stem Cell Transplantation for Haematological Diseases. <i>Blood</i> , 2015, 126, 3122-3122.	0.6	0
172	Long-Lasting HHV-6 Reactivation in Long-Term Adult Survivors After Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation. <i>Journal of Infectious Diseases</i> , 2014, 210, 567-570.	1.9	7
173	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. <i>Haematologica</i> , 2014, 99, 1486-1491.	1.7	25
174	Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies. <i>Haematologica</i> , 2014, 99, 1762-1768.	1.7	35
175	Quantification of two viral transcripts by real time PCR to investigate human herpesvirus type 6 active infection. <i>Journal of Clinical Virology</i> , 2014, 59, 94-99.	1.6	12
176	Antithymocyte Globulin before Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Study from the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 646-654.	2.0	24
177	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. <i>Blood</i> , 2014, 123, 3739-3749.	0.6	281
178	Human herpesvirus 6 reactivation before engraftment is strongly predictive of graft failure after double umbilical cord blood allogeneic stem cell transplantation in adults. <i>Experimental Hematology</i> , 2014, 42, 945-954.	0.2	17
179	Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1841-1846.	2.0	53
180	Sequential Regimen of Clofarabine, Cytarabine and Reduced Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) in Primary Treatment Failure. <i>Blood</i> , 2014, 124, 1228-1228.	0.6	2

#	ARTICLE	IF	CITATIONS
181	Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. a Retrospective Analysis on Behalf of Eurocord, ALWP and Cqwp-EBMT. Blood, 2014, 124, 187-187.	0.6	2
182	Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from		



#	ARTICLE	IF	CITATIONS
199	Effect of Graft Source on Alternative Unrelated Donor Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukaemia after: A Study from the SFGM-TC. Blood, 2014, 124, 2541-2541.	0.6	0
200	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 1230-1230.	0.6	1
201	Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome; A More Favorable Outcome after Fludarabine and Treosulfan Conditioning, a Survey on Behalf of the Chronic Malignancies Working Party of the EBMT. Blood, 2014, 124, 1216-1216.	0.6	0
202	<scp>BCR</scp>â€œ<scp>ABL</scp>1 molecular remission after ⁹⁰<scp>Y</scp>â€œpratumab tetraxetan radioimmunotherapy in <scp>CD</scp>22⁺<scp>P</scp>h⁺<scp>B</scp>â€œ<scp>ALL</scp>: proof of principle. European Journal of Haematology, 2013, 91, 552-556.	1.1	19
203	Comparison of Outcomes after Two Standards-of-Care Reduced-Intensity Conditioning Regimens and Two Different Graft Sources for Allogeneic Stem Cell Transplantation in Adults with Hematologic Diseases: A Single-Center Analysis. Biology of Blood and Marrow Transplantation, 2013, 19, 934-939.	2.0	22
204	Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 2013, 19, 1355-1360.	2.0	81
205	HHV-6 cell receptor CD46 expression on various cell subsets of six blood and graft sources: A prospective series. Journal of Clinical Virology, 2013, 56, 331-335.	1.6	6
206	Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, <scp>IV</scp> busulfan, and antithymocyte globulins (<scp>FB</scp>2 regimen) reducedâ€œintensity conditioning regimen (<scp>RIC</scp>) allogeneic stem cell transplantation (alloâ€œ<scp>SCT</scp>). European Journal of Haematology, 2013, 90, 177-186.	1.1	17
207	Characterization of various blood and graft sources: a prospective series. Transfusion, 2013, 53, 2020-2026.	0.8	13
208	Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood, 2012, 119, 2943-2948.	0.6	45
209	Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. Blood, 2012, 119, 2474-2477.	0.6	14
210	Clofarabineâ€œcontaining conditioning regimen for alloâ€œ<scp>SCT</scp> in <scp>AML</scp>/<scp>ALL</scp> patients: a survey from the Acute Leukemia Working Party of <scp>EBMT</scp>. European Journal of Haematology, 2012, 89, 214-219.	1.1	26
211	Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC. Biology of Blood and Marrow Transplantation, 2012, 18, 289-294.	2.0	51
212	Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3â€œITD molecular status for cytogenetically normal AML patients: A GOELAMS study. American Journal of Hematology, 2012, 87, 1052-1056.	2.0	20
213	Rituximab for the treatment of adult relapsed/refractory CD20 positive B-ALL patients: A pilot series. Leukemia Research, 2012, 36, 311-315.	0.4	11
214	Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Haematologica, 2011, 96, 1391-1394.	1.7	62
215	Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica, 2010, 95, 324-328.	1.7	98
216	Reply to K. Filanovsky et al. Journal of Clinical Oncology, 2010, 28, e117-e118.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome- ϕ -Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 911-918.	0.8	506
218	A phase II trial of high-dose imatinib mesylate for relapsed or refractory c-kit positive and Bcr-Abl negative acute myeloid leukaemia: The AFR-15 trial. <i>Leukemia Research</i> , 2009, 33, 1124-1126.	0.4	15
219	Reduced-intensity conditioning for allogeneic stem cell transplantation: 10 years later. <i>Current Opinion in Oncology</i> , 2009, 21, S1.	1.1	5
220	Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression. <i>International Journal of Hematology</i> , 2008, 88, 209-211.	0.7	22
221	Re-administration of a combination of chemotherapy+Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity. <i>Leukemia Research</i> , 2008, 32, 1321-1322.	0.4	5
222	Two cases of acute lymphoblastic leukaemia following acute myeloid leukaemia. <i>Leukemia Research</i> , 2008, 32, 1001-1003.	0.4	2
223	Long-Term Disease-Free Survival After Gemtuzumab, Intermediate-Dose Cytarabine, and Mitoxantrone in Patients With CD33+Primary Resistant or Relapsed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 5192-5197.	0.8	79
224	Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study From the SFGM-TC. <i>Journal of Clinical Oncology</i> , 2008, 26, 4940-4943.	0.8	98
225	Efficacy of Imatinib-Based Therapy in a Patient with Resistant NUP214-ABL1 T-Cell Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2007, 110, 4329-4329.	0.6	0
226	Acute Lymphoblastic Leukemia Occurring in Patient with Acute Myeloid Leukaemia: An Unrelated Leukemia Rather Than a Therapy-Related Malignancy. About 2 Cases.. <i>Blood</i> , 2006, 108, 4470-4470.	0.6	0
227	Allogeneic Stem Cell Transplantation with Reduced Intensity Conditioning Regimen (RIC) for Adult Patients with AML: Same Results in Secondary and De Novo AML.. <i>Blood</i> , 2006, 108, 3015-3015.	0.6	0
228	MIDAM Regimen (Mylotarg + Intermediate Dose Aracytin + Mitoxantrone) Is an Effective Combination of Chemo-Immunotherapy for Relapsed/Refractory CD33+ AML Patients.. <i>Blood</i> , 2006, 108, 1957-1957.	0.6	7
229	Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2005, 29, 1003-1007.	0.4	37
230	Overexpression of Her2/neu is observed in one third of adult acute lymphoblastic leukemia patients and is associated with chemoresistance in these patients. <i>Haematologica</i> , 2004, 89, 1399-401.	1.7	15
231	Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin. <i>Cancer Research</i> , 2002, 62, 2861-8.	0.4	72